186 related articles for article (PubMed ID: 21233532)
1. Important advances in the field of anti-dengue virus research.
Julander JG; Perry ST; Shresta S
Antivir Chem Chemother; 2011; 21(3):105-16. PubMed ID: 21233532
[TBL] [Abstract][Full Text] [Related]
2. Testing antiviral compounds in a dengue mouse model.
Schul W; Yip A; Shi PY
Methods Mol Biol; 2013; 1030():269-81. PubMed ID: 23821275
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of dengue antiviral candidates in vivo in mouse model.
Watanabe S; Vasudevan SG
Methods Mol Biol; 2014; 1138():391-400. PubMed ID: 24696350
[TBL] [Abstract][Full Text] [Related]
4. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
5. An iminosugar with potent inhibition of dengue virus infection in vivo.
Perry ST; Buck MD; Plummer EM; Penmasta RA; Batra H; Stavale EJ; Warfield KL; Dwek RA; Butters TD; Alonzi DS; Lada SM; King K; Klose B; Ramstedt U; Shresta S
Antiviral Res; 2013 Apr; 98(1):35-43. PubMed ID: 23376501
[TBL] [Abstract][Full Text] [Related]
6. Ten years of dengue drug discovery: progress and prospects.
Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis.
Herrero LJ; Zakhary A; Gahan ME; Nelson MA; Herring BL; Hapel AJ; Keller PA; Obeysekera M; Chen W; Sheng KC; Taylor A; Wolf S; Bettadapura J; Broor S; Dar L; Mahalingam S
Pharmacol Ther; 2013 Feb; 137(2):266-82. PubMed ID: 23103333
[TBL] [Abstract][Full Text] [Related]
8. Dengue Virus Evolution under a Host-Targeted Antiviral.
Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice.
Kuruvilla JG; Troyer RM; Devi S; Akkina R
Virology; 2007 Dec; 369(1):143-52. PubMed ID: 17707071
[TBL] [Abstract][Full Text] [Related]
10. Strategies for development of Dengue virus inhibitors.
Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
[TBL] [Abstract][Full Text] [Related]
11. Dengue vaccine: opportunities and challenges.
Hatch S; Mathew A; Rothman A
IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
[TBL] [Abstract][Full Text] [Related]
12. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.
Frias-Staheli N; Dorner M; Marukian S; Billerbeck E; Labitt RN; Rice CM; Ploss A
J Virol; 2014 Feb; 88(4):2205-18. PubMed ID: 24335303
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the development of a vaccine against dengue].
Guzmán MG
Acta Cient Venez; 1998; 49 Suppl 1():38-45. PubMed ID: 10030053
[TBL] [Abstract][Full Text] [Related]
14. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
Melino S; Paci M
FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
[TBL] [Abstract][Full Text] [Related]
15. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model.
Rathore AP; Paradkar PN; Watanabe S; Tan KH; Sung C; Connolly JE; Low J; Ooi EE; Vasudevan SG
Antiviral Res; 2011 Dec; 92(3):453-60. PubMed ID: 22020302
[TBL] [Abstract][Full Text] [Related]
16. In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries.
Rees CR; Costin JM; Fink RC; McMichael M; Fontaine KA; Isern S; Michael SF
Antiviral Res; 2008 Nov; 80(2):135-42. PubMed ID: 18606464
[TBL] [Abstract][Full Text] [Related]
17. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
Kitab B; Kohara M; Tsukiyama-Kohara K
Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the activity of 2'-C-methylcytidine against dengue virus replication.
Lee JC; Tseng CK; Wu YH; Kaushik-Basu N; Lin CK; Chen WC; Wu HN
Antiviral Res; 2015 Apr; 116():1-9. PubMed ID: 25614455
[TBL] [Abstract][Full Text] [Related]
19. The dengue virus non-structural 1 protein: risks and benefits.
Amorim JH; Alves RP; Boscardin SB; Ferreira LC
Virus Res; 2014 Mar; 181():53-60. PubMed ID: 24434336
[TBL] [Abstract][Full Text] [Related]
20. Animal models for studying dengue pathogenesis and therapy.
Chan KW; Watanabe S; Kavishna R; Alonso S; Vasudevan SG
Antiviral Res; 2015 Nov; 123():5-14. PubMed ID: 26304704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
